Contribution of PET/MRI in Locally Advanced Cervical Cancer

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

\[18 F\]fluorodeoxyglucose (18F-FDG) positron emission tomography-magnetic resonance imaging (PET/MRI) is a new hybrid imaging tool that has recently arrived in oncology, and is particularly promising. Its usefulness seems obvious in certain tumor types, but its place in the staging of cervical cancers has never been explored in a prospective trial to our knowledge. Previously, a comparative retrospective study from 2009 found a better sensitivity of PET fused to diagnostic MRI images compared to PET/CT (positron emission tomography/computed tomography) in the detection of metastatic lymph nodes (54 and 44% respectively). It was an a posteriori fusion of images, from images acquired by PET-CT.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients aged from 18 years old and over

• Patients with presumed cervical cancer of stages IB2 to IVA based on clinical data and pelvic MRI, undergoing pre-treatment assessment.

• For women of childbearing potential : Adequate contraception throughout study participation.

⁃ Note : enrollment in a concomitant clinical trial is authorized

Locations
Other Locations
France
Institut de cancérologie Strasbourg Europe
RECRUITING
Strasbourg
Contact Information
Primary
Claire VIT
promotion-rc@icans.eu
(0)3 88 25 85 29
Backup
Manon VOEGELIN
promotion-rc@icans.eu
(0)3 68 33 95 23
Time Frame
Start Date: 2023-10-12
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 50
Related Therapeutic Areas
Sponsors
Leads: Institut de cancérologie Strasbourg Europe

This content was sourced from clinicaltrials.gov

Similar Clinical Trials